Information for Colorado Prescribers of Prescription Drugs

Portrazza[®] (necitumumab)

- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.
- The products listed below represent the first generic products to market from the same therapeutic class as the Marketed Product (as determined by the USC therapeutic classification).^{1,2} This list is limited to three products and is not necessarily inclusive of all generic alternatives available.
- This list of generic products below does not imply that the products are interchangeable or have the same efficacy or safety as the Marketed Product. Please refer to each product's FDA-approved label and indication for further information.

Marketed Product:

BR	AND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	
P	ortrazza®	necitumumab	800 mg	Vial	1	0002-7716- 01	\$4,329.75

Generic Product(s):

35211 - GROWTH FACTOR INHIBITORS MAB³

There are no generic prescription drugs available from the same therapeutic class.

Portrazza® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

All trademarks are the property of their respective owners.

¹ Source: AnalySource[®]. Accessed on 01/01/2022. WAC reprinted with permission by First Databank Inc. All rights reserved.[©] 2022. http://www.fdbhealth.com/policies/drug-pricing-policy/.

² For some biologics, such as insulins, unbranded products are included in the list of "Generic Product(s)" if identified as "generics" in AnalySource[®].

³ Represents the USC classification of the marketed product. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-uniform-system-of-classification.pdf?la=en&hash=91EF697FDBFC81DF57A0EC816CA83E1BCC82DB28.